Gut Microbial Metabolites as a Bridge in Osteoporotic Rehabilitation for the Elderly: From Aging-Related Dysbiosis to Precision Non-Pharmacological Strategies Authors: Mei Tu, Wei Jiang, Yangfeng Huang Published: 2026 ABSTRACT AbstractBackground and ObjectiveOsteoporosis in the elderly represents a major public health challenge in aging societies. Although non-pharmacological rehabilitation has become a core intervention strategy, standard protocols yield highly variable responses across individuals. This review aims to systematically examine the bridging role of gut microbial metabolites in the pathogenesis and rehabilitation of osteoporosis in the elderly, explore the hypothesis that baseline microbial status influences the heterogeneity of rehabilitation outcomes, and propose a microbiota-targeted precision rehabilitation framework for older populations.MethodsThis narrative review systematically searched PubMed, Web of Science, Embase, Cochrane Library, Scopus, and CINAHL databases (January 2016 to May 2026). Original studies and reviews on naturally aged animal models and populations aged ≥60 years were included, with 56 articles retained for narrative synthesis.Key FindingsAging drives gut dysbiosis characterized by depletion of short-chain fatty acid (SCFA)-producing bacteria, accumulation of lipopolysaccharide (LPS) and trimethylamine N-oxide (TMAO), and disrupted bile acid metabolism. These alterations compromise intestinal barrier integrity and induce chronic low-grade inflammation, ultimately shifting the osteoblast-osteoclast balance toward bone resorption. Exercise training and dietary fiber supplementation can partially reverse these changes by elevating SCFA levels, suppressing NF-κB-mediated inflammatory pathways, and restoring intestinal barrier function. However, the translational gap between animal models and elderly populations, confounding effects of polypharmacy, poor long-term adherence, and inter-individual baseline differences constitute major barriers to translating mechanistic evidence into clinical rehabilitation.Clinical ImplicationsBaseline gut microbial status may be a core predictor of rehabilitation response, though this hypothesis requires prospective cohort validation. A stratified rehabilitation strategy based on microbial typing—“sensitive” individuals receiving standard protocols and “resistant” individuals receiving combined microbiome-targeted adjunctive therapy (including specific probiotic strains or synbiotics)—offers an actionable research direction for precision rehabilitation. Candidate stratification biomarkers such as the fecal SCFA-to-calprotectin ratio require prospective validation, and the development of home-detectable biomarkers remains a critical translational priority. The clinical translation of this framework depends on the accumulation of long-term follow-up data and the resolution of implementation barriers in real-world primary care settings. Notably, the mechanistic evidence underpinning this framework derives predominantly from animal and in vitro studies (high mechanistic certainty, low translational certainty), whereas clinical trial evidence remains limited to small, short-term, predominantly exploratory trials (low to moderate certainty for efficacy, very low for precision targeting); prospective clinical validation is therefore essential before routine implementation.Keywords: aged, osteoporosis, gut microbiota, microbial metabolites, short-chain fatty acids, gut-bone axis, rehabilitation, bone turnover Introduction Approximately 8.9 million osteoporotic fractures occur worldwide each year, with hip fractures carrying a 20–30% mortality rate within the first year.1 This figure reflects a reality long overlooked in drug development: the fundamental challenge in managing osteoporosis in the elderly is not a shortage of new drugs, but rather patients’ inability to adhere to long-term medication regimens. The one-year adherence rate for oral bisphosphonates is often below 50%. Denosumab, teriparatide, and romosozumab are effective, but concerns about atypical femoral fractures, osteonecrosis of the jaw, and financial burdens deter many older patients from sustained use.2 Non-pharmacological rehabilitation—encompassing exercise training, nutritional modulation, and lifestyle interventions—is thus transitioning from an adjunctive approach to a core management strategy. Current international guidelines recommend multicomponent exercise programs including progressive resistance training (2–3 times/week), weight-bearing aerobic exercise (3–5 times/week for 30–60 minutes), and balance/fall prevention training for elderly osteoporotic populations. However, a puzzling observation in rehabilitation practice is the marked variability in response to standardized protocols across elderly individuals. The same regimen—three weekly resistance training sessions combined with dietary guidance—may yield substantial bone mineral density (BMD) improvement in some patients while producing little effect in others.3 This heterogeneity is not anecdotal; it is a recurring pattern in rehabilitation research. Genetic background and baseline nutritional status offer partial explanations, but recent gut-bone axis research suggests that inter-individual differences in the gut microbiome may provide a deeper explanation. Over the past five years, more than a dozen reviews have systematically summarized the molecular pathways of the gut-bone axis.4–7 We do not intend to recapitulate these accounts. Instead, we focus on a more clinically challenging question: why does the same rehabilitation protocol produce such divergent outcomes in different elderly individuals? This question moves us from “how the microbiome affects bone” to the deeper issue of “whether and how the baseline microbial state may determine rehabilitation success”—a hypothesis that currently lacks direct prospective validation. Existing reviews in this field can be broadly categorized into three groups: mechanistic reviews that systematically map gut-bone molecular pathways,4–6 intervention reviews that summarize probiotic, prebiotic, or exercise effects on bone health,7 and aging-focused reviews that describe age-related microbial dysbiosis patterns.5 While these reviews have established the foundational knowledge, none has systematically addressed the clinical heterogeneity of rehabilitation responses or proposed a microbiota-based stratification framework tailored to elderly osteoporotic populations. The present review distinguishes itself by (i) centering on the variability of rehabilitation outcomes rather than general mechanism description; (ii) proposing a concrete SCFA/calprotectin-based stratification paradigm; and (iii) explicitly acknowledging the hypothesis-generating nature of the proposed framework and the evidence gaps that must be resolved before clinical implementation. A further methodological choice of this review warrants clarification: we prioritize microbial metabolites over taxonomic composition as the primary analytical lens. This choice is grounded in three considerations. First, metabolites are the direct functional outputs of microbial activity and the proximal mediators of host–microbe interactions, whereas taxonomic profiles reflect microbial identity but not necessarily functional state. Second, compositional data exhibit high inter-individual variability and poor reproducibility across populations and sequencing platforms, making them less reliable as clinical stratification markers. Third, metabolites are more directly modifiable through dietary and pharmacological interventions, offering clearer translational targets for precision rehabilitation. Consequently, a metabolite-centric framework provides greater translational value for moving from mechanistic understanding to actionable clinical strategies. Before proceeding, it is useful to define key terms. The gut microbiota refers to the entire community of microorganisms (bacteria, archaea, fungi, and viruses) inhabiting the gastrointestinal tract. The gut microbiome denotes the collective genome and functional gene repertoire of these microorganisms, encompassing their genetic material and metabolic potential. Microbial metabolites are small-molecule compounds produced by gut microbes through fermentation, biotransformation, and other metabolic activities, including short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), trimethylamine N-oxide (TMAO), and bile acid derivatives. The gut microbiota, comprising approximately 1014 microorganisms, produces metabolites including SCFAs, LPS, TMAO, and bile acid derivatives, engaging in continuous cross-talk with the immune, endocrine, and nervous systems.8,9 Aging is the most powerful driver of gut microbial structural and functional remodeling.10 Elderly osteoporotic patients exhibit characteristic dysbiotic patterns, the severity of which correlates significantly with the rate of BMD decline and fracture risk.11 The gut-bone axis is not a simple linear pathway but a complex network of immunological, metabolic, and neural signals.12 Advances in multi-omics technologies and gnotobiotic animal models are progressively decoding the “chemical language” of microbial metabolites, identifying novel targets for bone health interventions.13 The mechanisms by which microbial dysbiosis drives osteoporosis through intestinal barrier disruption, immune activation, and metabolic imbalance have been increasingly elucidated in animal studies.14,15 This review addresses three levels of evidence: (1) how aging remodels the gut microbial metabolic profile, (2) how rehabilitation training and nutritional interventions counteract these metabolic derangements, and (3) why current research still cannot definitively answer the question of “which patient should receive which intervention”—and what research frameworks are needed to address this gap. Review Methodology This narrative review followed a defined methodological framework. We systematically searched PubMed, Web of Science, Embase, Cochrane Library, Scopus, and CINAHL for literature published between January 2016 and May 2026, with emphasis on studies from 2023 to 2026. Embase was included to supplement European biomedical literature, Cochrane Library for high-quality systematic reviews and clinical trials, Scopus for broader multidisciplinary coverage, and CINAHL and SPORTDiscus for rehabilitation and exercise intervention topics. The search strategy combined the following terms: (“osteoporosis” OR “bone loss” OR “fracture”) AND (“aging” OR “elderly” OR “older adults” OR “senile”) AND (“gut microbiota” OR “microbiome” OR “intestinal flora”) AND (“microbial metabolites” OR “short-chain fatty acids” OR “SCFAs” OR “LPS” OR “TMAO” OR “bile acids”) AND (“gut-bone axis” OR “intestinal-bone axis”) AND (“rehabilitation” OR “exercise” OR “physical activity” OR “nutrition” OR “dietary intervention” OR “prebiotics” OR “probiotics”). We prioritized original studies based on naturally aged animal models (rather than acute ovariectomized [OVX] models) and populations aged 60 years and older. Interventions were restricted to exercise, nutritional supplementation, or their combination. Outcomes had to include at least one measure of gut microbial metabolites alongside BMD or bone turnover markers. The core exclusion criterion was the lack of independent analysis of older subgroups; studies that combined age groups without reporting data separately for participants aged ≥60 years were excluded. In vitro experiments, non-English or non-Chinese publications, conference abstracts, dissertations, and preprints were also excluded. Literature screening and quality assessment were independently completed by two authors, with inconsistent screening results resolved via cross-discussion and joint evaluation among all three authors. After removing duplicates and screening titles/abstracts, 187 potentially relevant records were identified. Full-text review of 89 articles led to the initial inclusion of 52 eligible studies. During the revision process, an additional targeted search for recent clinical evidence (2025–2026) was conducted in response to reviewer comments, resulting in the inclusion of 4 additional studies (2 randomized controlled trials, 1 meta-analysis, and 1 review), bringing the total to 56 eligible studies: 31 population-based studies (10 randomized controlled trials, 12 prospective cohort studies, and 9 cross-sectional studies), 18 animal experiments, and 7 reviews. As this is a narrative rather than systematic review, a PRISMA flowchart was not employed; however, detailed screening records are available upon request. The narrative synthesis was organized around the central theme of “metabolite alterations—bone regulatory pathways—rehabilitation response variability—translational bottlenecks.” As this study is a narrative review based on previously published literature, it does not involve direct human or animal subjects; therefore, ethical approval and informed consent were not required. The Aging Signature of Gut Microbiota and Its Metabolites in Elderly Osteoporosis Microbial Structural Degeneration and Metabolic Reprogramming The aging of the gut begins earlier and more insidiously than that of the skin. After age 65, the Firmicutes/Bacteroidetes (F/B) ratio begins an irreversible decline.16 The overall α-diversity of the gut microbiota decreases significantly, reducing the ecosystem’s resilience to external perturbations such as antibiotic exposure or dietary changes.17 At the phylum level, Firmicutes abundance decreases while Bacteroidetes proportion increases; the reduction in the F/B ratio is recognized as a hallmark of gut microbial aging.18 Changes at the genus and species levels carry greater pathophysiological significance. The depletion of butyrate-producing bacteria is particularly striking. Multiple population-based studies consistently report that Faecalibacterium prausnitzii accounts for 5–15% of total fecal bacteria in healthy adults, whereas in elderly osteoporotic patients, this proportion often falls below 1% on average, with some severe cases showing even lower levels.19 The loss of F. prausnitzii entails a double penalty: loss of butyrate synthesis and loss of a natural anti-inflammatory barrier—this bacterium directly inhibits NF-κB by secreting MAM protein.20 Concomitant depletion occurs in Roseburia, Eubacterium, and Clostridium clusters IV/XIVa.21 Opportunistic pathogens expand in turn. Enterobacteriaceae (including LPS-hyperproducing strains), Clostridium difficile, and hydrogen sulfide-producing bacteria increase substantially, shifting the gut ecosystem from a “probiotic-dominant” to a “pathobiont-driven” configuration.22 Work from Chinese research groups, using high-throughput absolute quantitative sequencing in Han Chinese elderly populations, confirmed that SCFA-producing bacteria are significantly less abundant in osteoporotic patients than in healthy age-matched controls, even after adjusting for age, sex, body mass index, and dietary intake.23 Multi-omics integration further revealed dose-response relationships between microbial compositional shifts, fecal metabolite profiles, and femoral neck BMD decline.24 Once microbial structure is disrupted, metabolic function undergoes global reprogramming. The intestinal metabolic microenvironment of elderly osteoporotic patients exhibits three synergistic damaging effects. SCFA reduction is the first signal. Short-chain fatty acids are produced by separate intestinal microbes: Bacteroidetes and Bifidobacterium mainly synthesize acetate, Veillonellaceae generate propionate, whereas Firmicute clusters serve as the dominant source of butyrate.25 Aging leads to simultaneous loss of these fermentative bacteria, lowering overall fecal SCFA levels by 50–65% relative to young healthy populations.26 Such metabolite scarcity impairs colon epithelial energy metabolism and weakens HDAC-mediated repression of pro-inflammatory genes.27 LPS elevation is the second signal. Gram-negative bacteria such as Enterobacteriaceae proliferate in the dysbiotic gut, and their outer membrane component LPS crosses the increasingly permeable intestinal wall to enter the circulation, establishing metabolic endotoxemia.28 LPS in the bloodstream activates the TLR4/NF-κB signaling pathway, which in turn suppresses intestinal FXR expression, directly linking inflammatory signals to bile acid metabolic disruption.29 TMAO is another accumulating microbial metabolite. Dietary choline, phosphatidylcholine, and carnitine are converted by the gut microbial CutC/D enzyme system to trimethylamine (TMA), which is absorbed and oxidized in the liver by FMO3 to TMAO. Beyond its established role as an independent cardiovascular risk factor, one animal study has suggested that TMAO may indirectly impair bone microcirculation through endothelial dysfunction and systemic oxidative stress.30 In animal models of senile osteoporosis, TMAO accumulation correlates negatively with trabecular bone volume fraction.31 It should be noted that the causal relationship between TMAO and bone metabolism is currently based primarily on animal studies and requires prospective human validation—findings from rodent models cannot be directly extrapolated to elderly patients without further investigation. Bile acid dysregulation is the third node. Primary bile acids synthesized in the liver are converted to secondary bile acids by microbial bile salt hydrolase (BSH) and 7α-dehydroxylase. Aging-related microbial changes reduce BSH activity, shifting the bile acid pool composition.32 Secondary bile acids regulate bone metabolism through FXR and TGR5 dual receptors: FXR activation upregulates Runx2 and Osterix expression in osteoblasts, while TGR5 signaling indirectly promotes bone formation via GLP-1 secretion. When bile acid metabolism is disrupted, FXR/TGR5 signaling becomes imbalanced, disturbing intestinal FGF19 secretion rhythm and consequently impairing both the circadian rhythm of osteocalcin and renal 1α-hydroxylation of vitamin D.13 Connecting these three events: SCFAs decrease → LPS increases → FXR is suppressed → osteocalcin becomes dysregulated. Moreover, LPS further suppresses intestinal FXR via TLR4-activated NF-κB, while TMAO-induced oxidative stress damages mitochondrial function in intestinal epithelial cells, compromising SCFA-dependent energy metabolism. The three metabolite classes interact at the “inflammation–metabolism–energy” interface, amplifying pathological effects exponentially. The microbial structural changes and metabolite abnormalities described above are distributed across multiple paragraphs. To facilitate integrated understanding, Table 1 presents a direct comparison of key indicators between healthy/younger states and elderly osteoporotic states, with specified magnitudes of change. It should be noted that the reference ranges and magnitudes of change in Table 1 are based on comprehensive assessment of multiple studies, and some heterogeneity exists across different investigations. Table 1Comparison of Gut Microbiota and Metabolite Profiles: Healthy/Younger States vs Elderly OsteoporosisParameterReference Value inHealthy/Younger StateElderlyOsteoporotic StateMagnitudeof ChangeKeyReferencesGut microbial α-diversity (Shannon index)3.5–5.02.0–3.5↓ 20–40%[16,17]Firmicutes/Bacteroidetes (F/B) ratio0.8–1.20.4–0.7↓ 30–50%[18]Faecalibacterium prausnitzii relative abundance5–15% of total microbiota<1%↓ 80–95%[19]Total butyrate-producing bacteria abundance10–20% of total microbiota<5%↓ 50–75%[13,20]Enterobacteriaceae (LPS-hyperproducing) relative abundance<1%3–8%↑ 3–8 fold[21]Fecal total SCFAs concentration80–120 μmol/g30–50 μmol/g↓ 50–65%[25,26]Circulating LPS level<0.5 EU/mL1.0–3.0 EU/mL↑ 2–6 fold[28,29]Circulating TMAO level<5 μmol/L8–15 μmol/L↑ 60–200%[30,31]Secondary/primary bile acid ratio1.5–2.50.8–1.2↓ 40–50%[22,32]Notes: ↑ = elevated indicator; ↓ = reduced indicator.Abbreviation: EU, endotoxin unit. Comparison of Gut Microbiota and Metabolite Profiles: Healthy/Younger States vs Elderly Osteoporosis Notes: ↑ = elevated indicator; ↓ = reduced indicator. Abbreviation: EU, endotoxin unit. Table 1 provides an overview of “outcomes”—what the microbiota has become and how far metabolites have deviated. But describing changes alone is insufficient; the critical question is how these changes are transmitted to bone. Each metabolite listed in Table 1 has its corresponding molecular receptors and downstream effectors. The following section dissects the complete signaling cascades through which these metabolites travel from the gut to bone and alter bone remodeling balance. “Leaky Gut” and the Inflammaging Vicious Cycle The intestinal mucosal barrier comprises three synergistic layers: the physical barrier (epithelial cells and tight junctions), chemical barrier (mucus layer and antimicrobial peptides), and immunological barrier (gut-associated lymphoid tissue). Aging concurrently erodes all three layers.33 At the physical barrier level, aging-related chronic low-grade inflammation and oxidative stress increase intestinal epithelial apoptosis and reduce proliferation. Tight junction proteins—Occludin and ZO-1—are downregulated and misassembled, increasing paracellular permeability.34 At the chemical barrier level, goblet cells secrete less MUC2 mucin, thinning the mucus layer and enlarging its pores. At the immunological level, intestinal sIgA secretion decreases and antimicrobial peptide expression declines, allowing greater microbial contact with the epithelium. Postmenopausal estrogen deficiency further compounds this degenerative process. Declining estrogen levels weaken ERβ signaling in intestinal epithelial cells, downregulating tight junction transcription, while simultaneously promoting TNF-α release, which damages epithelial function through a parallel pathway. Clinical data show that postmenopausal women have significantly elevated gut permeability markers, with increases correlating positively with circulating LPS and negatively with lumbar BMD.35 Once intestinal permeability increases, LPS and other endotoxins flood into the circulation, activate TLR4/NF-κB signaling, and drive monocyte polarization toward M1 pro-inflammatory macrophages, which release IL-1β, TNF-α, and IL-6—the hallmark of so-called “inflammaging”.36 Inflammaging impacts bone through multiple mechanisms. TNF-α and IL-1β suppress Runx2 and Osterix expression via NF-κB and AP-1 activation, directly impairing osteoblast differentiation.37 IL-6 and TNF-α upregulate RANKL expression in bone marrow stromal cells and osteoblasts while suppressing OPG production, substantially raising the RANKL/OPG ratio and accelerating osteoclast precursor maturation.38 Concurrently, the inflammatory environment upregulates PPARγ and C/EBPα while suppressing Runx2, skewing bone marrow mesenchymal stromal cell (BMSC) differentiation toward adipogenesis and exacerbating marrow adiposity. A self-reinforcing vicious cycle thus emerges: dysbiosis → reduced SCFAs/increased LPS → barrier damage → endotoxemia → TLR4/NF-κB activation → chronic inflammation → marrow adiposity and RANKL/OPG imbalance → increased resorption and reduced formation → worsening osteoporosis → reduced mobility and intestinal transit → further microbial deterioration.39,40 Once initiated, this cycle perpetuates itself. The immobility and impaired mastication resulting from bone loss further alter dietary patterns and intestinal motility, feeding back to the microbiota. It is important to recognize that this mechanistic model, while supported by animal studies, has not been fully validated in longitudinal human cohorts. Figure 1 illustrates the closed-loop nature of this self-amplifying gut-bone cycle. Understanding this circuit allows us to consider which intervention points are amenable to pharmacotherapy and which to physical rehabilitation. This horizontal schematic illustrates the closed pathological cycle linking aging gut dysbiosis to bone loss. Aging-related risk factors drive depletion of butyrate-producing beneficial microbes and overgrowth of pro-inflammatory pathobionts, which triggers three core metabolic abnormalities: decreased circulating SCFAs, accumulated LPS and TMAO, and disrupted bile acid signaling. These metabolites jointly damage intestinal mucosal barrier integrity (leaky gut) and induce sustained systemic inflammaging via TLR4/NF-κB inflammatory cascades. Chronic inflammation simultaneously suppresses osteogenic differentiation and accelerates osteoclast maturation, eventually causing senile osteoporosis. Reduced mobility and malnutrition secondary to bone loss further deteriorate gut microbial homeostasis, forming a self-amplifying vicious cycle. Key upstream signaling molecules (including TLR4 and NF-κB) are labeled in the figure; detailed bacterial species, tight junction proteins, specific inflammatory cytokines and downstream transcription factors are fully described in the text for visual conciseness. Core Molecular Pathways Through Which Microbial Metabolites Regulate Bone Homeostasis Immunomodulatory and Osteogenic Effects of SCFAs SCFAs influence bone through two principal routes: one immunological, the other directly osteogenic. Although they initiate independently, they converge functionally at their endpoints. The first route begins with HDAC inhibition. Butyrate inhibits HDAC, directing CD4⁺ T-cell differentiation toward the Treg lineage. This lineage choice is consequential—Tregs secrete IL-10 and TGF-β, which directly suppress NFATc1 in osteoclast precursors, whereas Th17 cells secrete IL-17, which exerts the opposite effect.41 Under steady-state or low-grade inflammatory conditions, SCFAs tend to indirectly suppress Th17 differentiation through Treg-dependent mechanisms.42 However, in specific inflammatory microenvironments, the effect of butyrate on Th17 differentiation may be more complex, with some studies reporting that high concentrations of butyrate can promote Th17 differentiation under certain conditions.43 In the aging gut, where SCFA concentrations are generally insufficient, the Treg/Th17 balance tilts toward pro-inflammation, and the brake on osteoclastogenesis fails.44 The second route is mediated by GPR41/GPR43 receptors, both expressed on BMSCs, osteoblast precursors, and mature osteocytes. SCFA binding to these receptors ultimately enhances Runx2 and Osterix transcription, increases ALP and osteocalcin activity, and promotes mineralized nodule formation.45 GPR43 also activates canonical Wnt signaling by inhibiting β-catenin phosphorylation and degradation. Butyrate further upregulates Wnt10b expression in BMSCs, amplifying osteogenic signaling in a Treg-dependent manner.46 The effects of the two routes are additive: enhanced osteogenesis and suppressed osteoclastogenesis—a “dual-benefit” regulatory configuration that positions SCFAs as core bone-protective targets. These mechanistic insights derive predominantly from cell-based and animal studies; their quantitative relevance to human bone metabolism requires further investigation. Promotion of Osteoclast Differentiation by the LPS/TLR4 Pathway LPS activates the TLR4/NF-κB pathway, upregulating RANK expression in osteoclast precursors to enhance RANKL sensitivity, while directly promoting NFATc1 transcription and nuclear translocation.47 TLR4 signaling also upregulates survival factors such as Mcl-1 and Bcl-xl, prolonging the functional lifespan of mature osteoclasts.48 A biologically relevant question arises: if LPS is so detrimental, why has evolution preserved TLR4? The answer lies in the distinction between acute and chronic inflammation. Under high-concentration acute LPS stimulation, TLR4 triggers massive TNF-α and NO production, which paradoxically induces osteoclast precursor apoptosis—a defense mechanism that eliminates damaged cells. However, the chronic “metabolic endotoxemia” of the aging osteoporotic microenvironment maintains circulating LPS at 1–10 ng/mL, precisely the optimal window for promoting osteoclastogenesis.49 This is why chronic low-grade inflammation is more damaging to bone than acute inflammation. Concurrently, TLR4 overactivation directly impairs osteogenesis by suppressing RUNX2 expression and activating S100B/ERK signaling, further compromising osteoblast differentiation and increasing osteoblast apoptosis. These findings, while robust in experimental systems, await confirmation in elderly-specific clinical cohorts. Convergence and Competition Among Three Pathways at the β-Catenin Node The three pathways converge on a common cellular resource—β-catenin. SCFAs and secondary bile acids trigger AKT-mediated β-catenin stabilization to drive osteogenic Runx2 expression.50 Conversely, LPS-TLR4 signaling activates NF-κB and depletes available IKK, weakening AKT signal transduction. Under aged osteoporotic conditions, protective SCFA and bile acid signaling declines, whereas LPS-related inflammatory cascades prevail, shifting β-catenin toward degradation. Targeted single-agent therapy fails to reverse this imbalance; concurrent restoration of fermentative metabolites is required to recover bone-forming β-catenin activity. A further interactive pathway involves 5-hydroxytryptamine (5-HT). Microbial metabolites regulate intestinal 5-HT synthesis by modulating Tph1 expression in enterochromaffin cells. Butyrate and secondary bile acids both influence Tph1 transcription through epigenetic and receptor-mediated mechanisms. Enteric 5-HT entering the circulation inhibits osteoblast proliferation via 5-HT1B/1D receptors while promoting osteoclastogenesis via 5-HT2B receptors—a “double-negative” effect that makes gut-derived 5-HT a negative regulator of bone homeostasis.51 Dysregulated gut 5-HT synthesis may be another underappreciated contributor to bone loss.52 These interacting networks reveal the non-linear, multi-target nature of the gut-bone axis. The comprehensive effects of altered gut microbial metabolites on bone turnover biomarkers and bone mineral density are summarized in Table 2. Notably, however, some studies have reached different conclusions—You et al found in mouse models that aging-related bone loss may be independent of the gut microbiome.43 Although this conclusion diverges from the majority of evidence, it underscores the importance of model selection (natural aging vs genetically engineered vs germ-free) in shaping experimental findings; extrapolation to elderly populations should not overgeneralize findings from any single model. Table 2Effects of Metabolite Changes on Bone Turnover Markers and Bone Mineral DensityMetabolite ChangeBone Formation Marker ResponseBone Resorption Marker ResponseBMD/Microstructure OutcomeDirection of EffectKey ReferencesSCFAs ↑P1NP ↑ 15–30%; OC ↑ 15–25%CTX-1 ↓ 10%–25%; TRACP-5b ↓ 10–20%Lumbar BMD ↑ 2%–5%; trabecular thickness ↑Protective[11,16,45]SCFAs ↓ (aging/dysbiosis)P1NP ↓ 20%–40%; OC ↓ 20–30%CTX-1 ↑ 30–60%Annual BMD loss rate ↑ 1.5–2 foldDamaging[12,17]LPS ↑ (metabolic endotoxemia)P1NP ↓ 20–35%CTX-1 ↑ 40%–80%; TRACP-5b ↑ 30–50%Osteoclast number ↑ 2–3 foldDamaging[19,25,38]TMAO ↑P1NP no change or ↓ 10–15%CTX-1 ↑ 15%–30%Trabecular bone volume fraction ↓ 10%–20%Damaging (weak–moderate)[21,30]Secondary bile acids (DCA) ↑Runx2/Osterix transcription ↑ 2–3 fold; OC ↑ 15–20%CTX-1 no significant changeBMSC osteogenic differentiation ↑Protective (cellular/animal)[22,51]Gut-derived 5-HT ↑Osteocalcin ↓ 20%–40%CTX-1 ↑ 20–50%Bone formation ↓, resorption ↑ (dual impairment)Damaging[41,47]Notes: ↑ = elevated level / enhanced effect; ↓ = reduced level / suppressed effect.Abbreviations: P1NP, procollagen type I N-terminal propeptide; OC, osteocalcin; CTX-1, C-terminal telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphatase 5b; BMD, bone mineral density; BMSC, bone marrow mesenchymal stromal cell; DCA, deoxycholic acid; 5-HT, 5-hydroxytryptamine. Effects of Metabolite Changes on Bone Turnover Markers and Bone Mineral Density Notes: ↑ = elevated level / enhanced effect; ↓ = reduced level / suppressed effect. Abbreviations: P1NP, procollagen type I N-terminal propeptide; OC, osteocalcin; CTX-1, C-terminal telopeptide of type I collagen; TRACP-5b, tartrate-resistant acid phosphatase 5b; BMD, bone mineral density; BMSC, bone marrow mesenchymal stromal cell; DCA, deoxycholic acid; 5-HT, 5-hydroxytryptamine. Figure 2 maps the convergence and competition of these three pathways at the β-catenin decision node. The reversibility of these pathways provides the theoretical basis for rehabilitation interventions—SCFAs can be replenished through dietary fiber, LPS can be reduced through exercise, and FXR can be reactivated by metabolites. It must be emphasized, however, that the above pathway evidence derives primarily from animal experiments and in vitro studies, and direct validation in elderly populations remains limited. This schematic shows three independent but mutually interactive signaling axes mediated by major gut microbial metabolites. SCFAs exert dual bone-protective effects via HDAC-Foxp3-Treg anti-osteoclast pathway and GPR41/GPR43-Wnt/β-catenin osteogenic pathway. Circulating LPS triggers inflammatory bone loss through TLR4-NF-κB-NFATc1 cascade. Bile acids activate FXR/TGR5 osteogenic signals, while gut-derived 5-HT inhibits bone turnover. SCFAs counteract LPS-induced inflammation; SCFAs and bile acids synergistically promote osteogenesis, whereas inflammatory LPS signaling blocks bile acid protective signals. Key signaling intermediates (including HDAC, Foxp3, GPR41/GPR43, Wnt/β-catenin, TLR4, NF-κB, NFATc1, FXR, and TGR5) are labeled in the figure; specific downstream cytokines, kinases and minor regulatory molecules are fully described in the manuscript text. How Rehabilitation Interventions Reshape Microbial Metabolites and Affect Bone Outcomes The preceding section has outlined the convergence and competition of SCFA, LPS/TLR4, and bile acid signaling pathways at the β-catenin node (Figure 2). A common feature of these pathways is their dynamic reversibility—SCFAs can be restored through dietary fiber supplementation, LPS can be reduced through regular exercise, and FXR can be reactivated by metabolites. This provides the theoretical foundation for rehabilitation interventions: correcting microbial metabolite abnormalities should, in theory, improve bone outcomes. The question is how much of this logic has been validated in elderly populations. Figure 3 illustrates this synergistic pathway, but how far its theoretical arrows can travel under real-world conditions warrants scrutiny. This schematic illustrates the synergistic gut-protective and bone-protective effects of standardized exercise and targeted nutritional intervention. Appropriate aerobic and resistance training, together with supplementary fiber, minerals and microecological preparations, jointly elevate circulating SCFAs, reduce harmful LPS and TMAO, and restore balanced bile acid metabolism, thereby repairing intestinal barrier integrity and inhibiting TLR4/NF-κB mediated systemic inflammaging. The optimized intestinal microenvironment rebalances bone turnover to slow age-related bone loss. Notably, over-strenuous exercise elevates cortisol and impairs gut barrier function to counteract bone benefits. Key intervention targets and metabolite classes are labeled in the figure; detailed alterations in gut flora, intestinal tight junction proteins and specific inflammatory cytokines are elaborated in the main text. Exercise Rehabilitation Conventional wisdom holds that exercise protects bone primarily through mechanical loading. Although true, this explanation is incomplete. Recent studies indicate that exercise also constitutes a powerful indirect bone-protective axis by extensively remodeling the gut microbiota.16 Regular aerobic and resistance training effectively alters the gut microbiota composition of sedentary elderly populations. Specifically, butyrate producers—particularly F. prausnitzii and Roseburia—increase substantially, α-diversity improves, and the F/B ratio normalizes. Fecal and circulating SCFA concentrations rise significantly after exercise interventions, with the magnitude of increase correlating positively with femoral neck BMD improvement.17 Exercise also reduces circulating LPS and inflammatory markers including TNF-α and IL-6. Current international rehabilitation guidelines for elderly osteoporosis recommend a multicomponent approach: moderate-intensity aerobic exercise (3–5 times/week, 30–60 minutes per session), progressive resistance training (2–3 times/week, targeting major muscle groups), and balance/fall prevention training (at least 2–3 times/week). These recommendations are primarily based on mechanical loading and neuromuscular benefits; their optimization for microbial modulation remains an area of active investigation. However, exercise is not “more is better.” Prolonged, high-intensity overload exercise elevates cortisol and adrenaline substantially. Cortisol, acting through the glucocorticoid receptor, suppresses intestinal epithelial proliferation and tight junction expression, paradoxically disrupting microbial homeostasis and the intestinal barrier.17,24 Excessive mechanical loading may also activate osteocyte apoptosis. This “inverted U-shaped” relationship is particularly problematic in elderly populations—reduced cardiopulmonary reserve and degenerative joint changes narrow the safety window for high-intensity exercise considerably. Nutritional Modulation The core principle of nutritional modulation is providing appropriate metabolic substrates to the microbiota. Dietary fibers—including inulin, fructo-oligosaccharides, and resistant starch—are the primary carbon sources for SCFA production. Dietary fiber exerts protective skeletal effects via three distinct pathways. First, elevated SCFA levels trigger GPR41 and HDAC-related inhibitory signaling cascades. Second, a more acidic gut environment boosts calcium solubility and uptake through TRPV6 channels. Third, altered epithelial PTHrP secretion indirectly modulates systemic bone turnover.52 Clinical trials in postmenopausal cohorts show daily intake of 10–20 g inulin-type fructans raises intestinal calcium absorption by around 15% to 20%. Calcium, vitamin D, and vitamin K all carry bone-regulating properties shaped by gut microbial metabolism. Vitamin D is not only activated by renal CYP27B1; gut microbes also express CYP27B1 and participate in local vitamin D activation. Vitamin K2 requires microbial menaquinone reductase for effective recycling—age-related microbial decline directly compromises osteocalcin γ-carboxylation. Magnesium absorption is similarly regulated by microbial metabolic activity.46 A caveat is the “metabolic inertia” phenomenon in elderly populations. The abundance of genes encoding carbohydrate-active enzymes (CAZymes) and polysaccharide utilization loci (PULs) in the aged gut microbiome declines substantially. Without sufficient PULs, the gut cannot efficiently ferment supplemented inulin or resistant starch into SCFAs; instead, fiber accumulates in the colon and undergoes abnormal fermentation, producing flatulence and discomfort that reduce adherence. In other words, simple fiber supplementation may be minimally beneficial—or even counterproductive—for elderly subgroups with severely degraded fermentation capacity. Combined Rehabilitation and Individual Variability Exercise remodels the microbiome but cannot supply metabolic substrates; fiber supplies substrates but cannot directly increase microbial diversity. Their combination—integrated rehabilitation—may achieve “1+1>2” through multi-target intervention. Exercise increases intestinal motility, shortens transit time, and reduces pathogenic colonization; precisely matched dietary fiber and micronutrients provide substrates for beneficial bacteria. Recent clinical trials have begun to evaluate these combined approaches. A randomized double-blind placebo-controlled trial of the synbiotic medical food SBD111 (NCT05009875) in 286 early postmenopausal women did not show significant bone loss reduction in the full cohort, but a prespecified subgroup analysis revealed a 0.97% reduction in hip BMD loss among osteopenic participants with BMI ≥30.53 In vitro experiments confirmed that SBD111 improved gut barrier function, reduced inflammatory cytokine secretion, and inhibited osteoclast activity.53 Another randomized double-blind placebo-controlled trial demonstrated that Limosilactobacillus fermentum CCFM1126 supplementation significantly increased BMD, elevated serum calcium and 25-hydroxyvitamin D levels, and reshaped gut microbiota composition in postmenopausal women.54 Meta-analyses have synthesized this emerging evidence. A meta-analysis of 10 RCTs encompassing 732 patients found that probiotic/synbiotic supplementation significantly improved lumbar spine BMD (SMD: 0.85; 95% CI: 0.01–1.69) without increasing adverse events.55 A separate meta-analysis reported significant increases in P1NP (MD = +8.4 μg/L; 95% CI: 3.1–13.7).48 The gut microbiome exerts systemic effects beyond the intestinal tract, with emerging evidence linking microbial dysbiosis to metabolic dysfunction through the brain–gut–liver axis.56 This broader perspective supports the rationale for microbiome-targeted strategies in aging-related disorders, including osteoporosis. Short-term (8–24 weeks) small-sample clinical studies indicate that synbiotic supplementation combined with mild aerobic exercise improves physical function, reduces frailty indices, and attenuates BMD decline in elderly sarcopenic or osteopenic populations.23,52 However, these studies are limited by sample sizes of 30–80 participants, follow-up durations rarely exceeding one year, and lack of rigorous blinding and placebo controls. More importantly, most of these studies excluded multi-medication patients, creating a gap between the study population and the complexity of real-world elderly patients. Individual variability deserves attention. Although direct validation of “baseline microbiota predicting rehabilitation response” is currently lacking, several lines of indirect evidence support the plausibility of this hypothesis. A cross-sectional study of postmenopausal osteoporotic women found that baseline F. prausnitzii abundance was independently and positively correlated with lumbar BMD (r=0.34, P<0.01).23 Another high-throughput sequencing study in Han Chinese elderly further showed that each order-of-magnitude decrease in SCFA-producer absolute abundance was associated with an approximately 1.5-fold increase in the risk of femoral neck BMD decline14. In the exercise intervention domain, Dou et al found that post-exercise butyrate elevation correlated positively with BMD improvement, but did not report whether baseline butyrate levels could predict this response.16 Taken together, a clear cross-sectional association has been established between baseline microbiota and BMD, but its predictive value for rehabilitation outcomes requires prospective validation. No study to date has directly demonstrated that “baseline SCFA levels can predict post-rehabilitation BMD changes”—this represents the evidence gap for the core hypothesis of this review, and will be explicitly acknowledged in Current Bottlenecks and Translational Gaps in Precision Rehabilitation. Exercise training and nutritional modulation have complementary yet distinct effects on microbial regulation, and their synergy is not simply additive. Evidence stratification in Table 3 follows standard clinical grading: preclinical animal research < small exploratory trials < controlled population studies < large randomized controlled trials. Table 3Key Characteristics, Evidence Levels, and Limitations of Rehabilitation Intervention StudiesIntervention TypeStudy Population/ModelSample SizeIntervention DurationMain BenefitsCritical LimitationsEvidence LevelKey ReferencesAerobic + resistance exerciseElderly (60–75 years, sedentary)30–1208–24 weeksSCFAs ↑ 30%–50%; femoral neck BMD ↑ 1–3%Most lack control groups; no fracture endpoints; short follow-upModerate (population studies)[16,45,51]Dietary fiber (inulin/FOS)Postmenopausal women20–604–12 weeksCalcium absorption ↑ 15%–20%; SCFAs ↑ 15%–25%Small samples; predominantly crossover design; no long-term BMD dataModerate (RCTs, but small)[52]Synbiotics + aerobic exerciseElderly sarcopenia/osteopenia30–808–24 weeksPhysical function improvement; BMD decline attenuated 0.5%–1.5%/yearUnblinded; no placebo control; multi-medication patients excludedLow–moderate (small exploratory)[25,52]Probiotics/synbioticsOVX mice (8–12 weeks old); postmenopausal women (RCTs)8–15 per group (animal); 732 patients (meta-analysis)4–12 weeks (animal); 3–12 months (human RCTs)BMD ↑ 5–15% in animal models; lumbar BMD significantly improved in human meta-analysis (SMD: 0.85; 95% CI: 0.01–1.69)OVX model ≠ natural aging; human RCTs limited by heterogeneity, short follow-up, and small samples; negative full-cohort results in some trialsModerate (RCT meta-analyses)[23,53,55]Combined exercise + nutritionElderly osteopenia20–5012–24 weeksFrailty index ↓; comprehensive physical function improvementHigh protocol heterogeneity; insufficient confounder controlLow (exploratory)[25,52]Abbreviations: FOS, fructo-oligosaccharides; SCFAs, short-chain fatty acids; BMD, bone mineral density; OVX, ovariectomized; RCT, randomized controlled trial; SMD, standardized mean difference. Key Characteristics, Evidence Levels, and Limitations of Rehabilitation Intervention Studies Abbreviations: FOS, fructo-oligosaccharides; SCFAs, short-chain fatty acids; BMD, bone mineral density; OVX, ovariectomized; RCT, randomized controlled trial; SMD, standardized mean difference. Figure 3 outlines this synergistic logic at three levels—intervention input, microecological remodeling, and bone homeostasis output—with solid arrows indicating established pathways and dashed arrows indicating links requiring further validation. In the real world, the sustainability of an exercise prescription depends on patient adherence, and the efficacy of dietary fiber depends on the gut’s remaining fermentation capacity. Current Bottlenecks and Translational Gaps in Precision Rehabilitation Several critical barriers currently prevent the translation of gut-bone axis mechanistic evidence into routine clinical rehabilitation for elderly osteoporotic patients. These barriers are not merely technical but reflect fundamental differences in evidence hierarchy. Model Mismatch and Evidence Hierarchy Animal experimental data suggest that gut-bone axis rehabilitation approaches are almost uniformly effective. In OVX mice, exercise training significantly recovers BMD, probiotic gavage doubles SCFA levels, and fecal microbiota transplantation (FMT) even “transplants” bone-protective effects. The problem is that these experiments use 8-week-old mice—their microbiota have not yet aged, their immune systems are intact, and their intestinal barriers have not been eroded by time. Identical interventions tested on 22-month senescent mouse models produce only half the therapeutic effect. This model mismatch directly explains why many intervention strategies that perform excellently in OVX young mice show substantially diminished effects when tested in elderly population clinical trials. This limitation must be considered when interpreting preclinical findings. Critically, the evidence base for the gut-bone-rehabilitation relationship spans a wide spectrum: mechanistic pathways are well-established in cell culture and animal models (high mechanistic certainty, low translational certainty); cross-sectional associations between microbial composition and BMD are consistent in observational studies (moderate certainty for association, low for causation); and RCT evidence for microbiome-targeted rehabilitation remains limited to small, short-term, predominantly exploratory trials (low to moderate certainty for efficacy, very low for precision targeting). Confounding Factors The gap from animals to humans is substantial; from research conditions to real-world clinical environments, it is even larger. Elderly osteoporotic patients almost invariably take two or more medications concurrently—proton pump inhibitors (PPIs) alter gastric pH and microbial colonization niches, antibiotics directly remodel microbial structure, and metformin increases Akkermansia muciniphila abundance via AMPK activation. The magnitude of these drug effects far exceeds that of 150 minutes of moderate-intensity exercise per week. Rehabilitation studies typically exclude multi-medication patients at enrollment, but the real world does not provide such a “clean” setting. The interaction between polypharmacy and rehabilitation efficacy remains severely understudied. Adherence and Rebound Twelve weeks of rigorous intervention does improve the microbiome measurably. However, 4–8 weeks after cessation, the microbiome returns to baseline. Sustained benefit requires lifelong maintenance, yet adherence rates for long-term rehabilitation protocols in elderly populations are concerning in clinical practice. A 2026 survey of 1,006 older Americans found that only 30% of individuals aged ≥65 years completed all prescribed physical therapy home exercises; systematic reviews similarly indicate that adherence rates for exercise programs in older adults range from 21% to 83% when measured by categorical thresholds, with unsupervised long-term adherence being particularly poor. In the Chinese context, community-based rehabilitation adherence faces additional challenges, including limited family support, economic constraints, and insufficient professional supervision. Data from domestic studies suggest that adherence to home-based exercise programs among Chinese elderly with chronic conditions is substantially lower than in supervised settings, though specific osteoporosis rehabilitation adherence data remain sparse. Lack of Predictive Tools Finally, we still cannot answer the question of “who is suited to exercise.” Candidate biomarkers such as baseline SCFAs, F. prausnitzii abundance, and serum zonulin are numerous, but none has been prospectively validated. The core hypothesis of this review—“baseline microbiota determines rehabilitation success”—currently lacks direct human evidence: no study has directly compared BMD responses to the same rehabilitation protocol between high-baseline SCFA and low-baseline SCFA groups. This evidence gap urgently requires further investigation. Future Perspectives: Toward Microbiome-Targeted Precision Rehabilitation for the Elderly Addressing the four obstacles outlined above requires a systematic approach that integrates stratification, sensitization, dynamic monitoring, and cohort validation. Rather than viewing these as discrete steps, they should be understood as interconnected components of a continuous learning healthcare system. It is essential to emphasize that the framework described below remains a research paradigm and hypothesis-generating model; its clinical applicability depends entirely on prospective validation in large-scale cohorts. Stratification The core challenge in stratification is choosing the right indicators. Available candidates—fecal SCFA profiles, calprotectin, zonulin, LPS-binding protein, and F. prausnitzii abundance—are abundant, but evidence is lacking. The most promising composite marker may be the SCFA/calprotectin ratio: Higher values of this fermentation-inflammation composite index reflect intact fermentative function and milder systemic inflammation, making standard rehabilitation more likely to succeed; lower ratios indicate a need for more intensive initial intervention. This hypothesis requires prospective validation in a thousand-patient cohort. A critical gap in the current literature is the absence of head-to-head comparisons of different candidate markers within the same elderly population. Future studies should systematically evaluate the predictive performance of fecal biomarkers, plasma markers, and microbial composition data to identify the most cost-effective stratification strategy. Sensitization Strategies Once stratification is established, sensitization strategies can be precisely deployed. For patients with baseline F. prausnitzii below 1% and butyrate below 5 μmol/g, standard rehabilitation is nearly ineffective, necessitating adjunctive use of specific probiotic strains (eg, Akkermansia muciniphila or Clostridium butyricum) or targeted FMT. However, randomized controlled trial evidence for FMT in osteoporosis is currently absent; the bone-protective effects demonstrated in animal experiments are a considerable distance from clinical application. Additionally, for elderly patients taking PPIs, supplementation with butyrate-producing strains may be added to the rehabilitation protocol to counteract PPI-induced microbial changes; for patients taking metformin, its intrinsic microbial regulatory effects should be considered to avoid over-intervention. Dynamic Monitoring Ideally, a dynamic monitoring system should be established—tracking exercise volume and heart rate variability via wearable devices, monitoring SCFAs and bile acids via routine fecal testing, and fitting these data to bone turnover markers using machine learning models. This approach is far more precise than the conventional “one microbiome measurement at baseline, one BMD measurement at six months” paradigm. Technology is no longer the bottleneck; the bottleneck is who will establish and validate this model. The integration of wearable technology into community-based rehabilitation programs represents a particularly promising avenue for the Chinese context, where smartphone penetration is high and mobile health platforms are rapidly expanding. Pilot programs should be designed to test the feasibility and patient acceptability of these approaches. Local Cohorts and Community Implementation China has a natural advantage in this regard. With over 200 million people aged 65 years and older, urbanization and primary care networks provide favorable conditions for long-term follow-up. However, cohort studies in the field of elderly osteoporosis rehabilitation in China remain relatively limited, and baseline microbial characteristics vary significantly across regions. Establishing a natural aging rehabilitation cohort with at least 24 months of follow-up—with baseline metagenomic and metabolomic profiling, randomization to standardized exercise, individualized nutrition, or combined protocols, and endpoints of annual BMD change and incident fractures—could answer all the questions posed above: Who is exercise-sensitive? Who needs probiotic support? Who must adhere lifelong? The establishment of such a cohort would also provide a validation platform for candidate markers such as the SCFA/calprotectin ratio. Importantly, the successful translation of these research findings into community practice requires overcoming significant implementation barriers, including the lack of reimbursement mechanisms for microbiome testing and the shortage of trained personnel to deliver personalized rehabilitation prescriptions in primary care settings. Clinical Decision Pathway (Research Framework) Based on the above stratified rehabilitation logic, a five-step clinical decision pathway can be preliminarily constructed as a conceptual research framework: (1) baseline fecal SCFA and calprotectin testing for all osteoporotic patients aged ≥65 years; (2) those with SCFA/calprotectin ratio above threshold enter the standard exercise + nutrition rehabilitation protocol; (3) patients with low levels of the fecal SCFA-to-calprotectin composite marker require adjunct probiotic intervention or synbiotics in addition to the standard protocol; (4) reassess SCFAs and bone turnover markers after 3 months of intervention, adjusting subsequent protocols according to changes; (5) patients with severe dysbiosis and refractory to conventional intervention may be considered for FMT (under strict supervision). This decision pathway remains a research framework, and the validity and thresholds of each node require validation in cohort studies. It is important to emphasize that before this pathway can be adopted in routine practice, cost-effectiveness analyses and implementation research in real-world primary care settings are essential. The complete closed-loop pathway from baseline screening to long-term follow-up is presented in Figure 4. This schematic 5-step workflow illustrates the translational clinical paradigm of microecology-targeted individualized rehabilitation for elderly osteoporosis. All patients receive baseline gut microbiota and intestinal barrier biomarker screening to distinguish rehabilitation-sensitive and resistant populations. Sensitive individuals receive standard exercise and nutritional intervention, while resistant patients adopt combined microecological adjuvant therapy. Real-time multi-dimensional physical and biochemical monitoring data are integrated into artificial intelligence algorithms to dynamically adjust personalized rehabilitation plans, forming a short-term feedback loop. Long-term aging cohort follow-up evaluates clinical bone outcomes, and cohort big data optimizes microbial screening thresholds to upgrade early patient stratification strategies, constructing a complete long-cycle precision rehabilitation closed loop. For visual conciseness, detailed detection indicators, subdivided intervention regimens, multi-omics parameters and follow-up endpoints are omitted from the figure and elaborated in the manuscript text. Limitations of This Review This narrative review has several methodological limitations that should be considered when interpreting its findings. First, narrative reviews do not employ systematic search and PRISMA protocols; literature inclusion inevitably carries subjective bias. Although clear search strategies and inclusion criteria were established, different investigators may interpret the same evidence differently. Second, the majority of included clinical studies are cross-sectional or small-sample pre-post designs, lacking the highest level of evidence for causal inference. Third, considerable heterogeneity across studies in microbiome sequencing platforms (16S rRNA vs metagenomic sequencing), metabolite quantification methods, and BMD measurement devices precludes quantitative synthesis; our conclusions should be understood as directional integration rather than precise effect estimation. Fourth, species differences between animals and humans, and the inferential gap between OVX models and natural aging models, cannot be ignored. The molecular pathway evidence cited in Core Molecular Pathways Through Which Microbial Metabolites Regulate Bone Homeostasis derives primarily from animal experiments and in vitro studies, and direct validation of these mechanisms in elderly populations remains limited—this is a major constraint on the translational relevance of our conclusions. Fifth, we did not systematically address other cross-organ axes such as the gut-muscle-bone axis or the gut-brain-bone axis. Sixth, the core hypothesis of “baseline microbiota typing guiding rehabilitation stratification” lacks direct human evidence and is primarily based on mechanistic derivation and logical inference. Seventh, the “precision rehabilitation” pathway described here currently rests primarily on logical deduction and mechanistic plausibility, without large-scale evidence-based validation. In the Chinese healthcare context, the proposed stratification strategy faces additional practical obstacles. Fecal SCFA and calprotectin testing has not yet been incorporated into routine primary care laboratory services, and quality control standards and reference ranges lack calibration from multi-center domestic data. Clinical studies of specific probiotic strains (such as Akkermansia muciniphila) and synbiotics in domestic elderly populations are extremely limited; their pricing and health insurance coverage as “rehabilitation adjuncts” remain unclear, raising accessibility concerns for economically disadvantaged elderly patients. Community rehabilitation systems lack multidisciplinary professionals capable of interpreting microbiome testing results and adjusting exercise/nutrition protocols accordingly—this is particularly pronounced in rural and underdeveloped areas. These structural shortcomings mean that even if the stratified rehabilitation strategy is theoretically valid, its translation from tertiary hospitals to communities and homes faces far more complex real-world constraints than laboratory research would suggest. These limitations are not unique to this review but represent shared challenges facing the entire field of gut-bone axis rehabilitation research. This is precisely why the natural aging cohort called for in Future Perspectives: Toward Microbiome-Targeted Precision Rehabilitation for the Elderly is so urgently needed. Conclusion Throughout the process of writing this review, one finding has repeatedly drawn attention: adherence rates for long-term rehabilitation protocols in real-world elderly populations are far lower than expected; even under supervised research conditions, the proportion who fully adhere to the original protocol after one year remains small. This means that even if we extend the molecular pathways of the gut-bone axis to a fourth, a fifth, even if we refine stratification markers to single-strain resolution, as long as patients cannot continue the protocol beyond the research setting, our “precision” remains precision only on paper. Returning to the three core questions that motivated this review: First, how does aging remodel the gut microbial metabolic profile? Aging drives a characteristic triad of metabolic derangements: depletion of SCFA-producing bacteria (especially F. prausnitzii), accumulation of LPS and TMAO, and disruption of bile acid metabolism. These alterations converge to compromise intestinal barrier integrity and induce chronic low-grade inflammaging, shifting the osteoblast-osteoclast balance toward net bone resorption. Second, how do rehabilitation training and nutritional interventions counteract these metabolic derangements? Moderate exercise and dietary fiber supplementation can partially reverse these changes by elevating SCFA levels, suppressing NF-κB-mediated inflammatory pathways, and restoring intestinal barrier function. However, these effects are subject to an “inverted U-shaped” dose-response (for exercise) and “metabolic inertia” (for fiber), and their magnitude in elderly populations is substantially smaller than that observed in young animal models. Third, why can we not yet determine which patient should receive which intervention? The translational gap arises from four interlocking barriers: model mismatch between young OVX animals and aged humans, confounding by polypharmacy in real-world elderly patients, poor long-term adherence to rehabilitation protocols, and the complete absence of prospectively validated predictive biomarkers. The hypothesis that baseline microbial status determines rehabilitation responsiveness remains mechanistically plausible but clinically unproven. Thus, a more pressing question is not “how microbial metabolites regulate bone”, but “how microbial metabolites can become a rehabilitation tool that patients can take home.” From this perspective, the most valuable discovery may not be a new pathway but a simple, home-detectable biomarker panel—one that lets older adults know “what state my microbiome is in today, and whether I am exercising correctly.” The stratified rehabilitation framework proposed in this review—screening for the SCFA/calprotectin ratio, distinguishing “sensitive” from “resistant” individuals, and deploying adjunctive microbiome-targeted therapies for the latter—represents a conceptually coherent but hypothesis-generating research direction. Its clinical translation depends on prospective cohort validation, the development of point-of-care diagnostic tools, and the accumulation of long-term fracture endpoint data. This requires gut-bone axis research to move beyond the fences of laboratories and clinical research centers and into communities and homes. China’s 200 million older adults provide a real-world foundation; what is lacking is a systematic, interdisciplinary research framework designed around long-term follow-up rather than short-term effects. The purpose of this review is to outline the boundaries and priorities of that framework, acknowledging that the path from microbial biomarker discovery to community-based rehabilitation delivery will require sustained collaborative effort across clinical, research, and healthcare policy domains. Acknowledgments We thank the entire research team for the support and assistance with this study. Funding Statement This work was supported by the Health Commission of Mianyang City (Grant No. 2024078). Declaration of AI Use During manuscript preparation, artificial intelligence tools were adopted to assist language polishing, English translation and conceptual schematic drawing. We confirm that all content in this manuscript is original and factually accurate. The AI tools used include Doubao (Version 13.3.0) for linguistic refinement, translation and preliminary graphic design, and KnowS for figure creation. We have reviewed the terms of service for all utilized AI tools and confirm that all AI-generated materials comply with the journal’s publication standards. We hold complete legal rights to publish all AI-assisted texts and figures, and have obtained all necessary authorization for submission. All authors take full responsibility for the integrity of the manuscript and the accuracy of all cited references. All versions of figures and corresponding prompt records are archived by the authors for editorial inspection when required. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare no competing interests. References